TimesSquare Capital Management LLC cut its stake in Boston Scientific Corporation (NYSE:BSX) by 5.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,624,075 shares of the medical equipment provider’s stock after selling 146,125 shares during the period. TimesSquare Capital Management LLC owned 0.19% of Boston Scientific Corporation worth $76,544,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Sivik Global Healthcare LLC raised its stake in shares of Boston Scientific Corporation by 8.3% in the third quarter. Sivik Global Healthcare LLC now owns 260,000 shares of the medical equipment provider’s stock worth $7,584,000 after acquiring an additional 20,000 shares during the last quarter. Norinchukin Bank The raised its stake in shares of Boston Scientific Corporation by 7.5% in the third quarter. Norinchukin Bank The now owns 102,128 shares of the medical equipment provider’s stock worth $2,979,000 after acquiring an additional 7,097 shares during the last quarter. Icon Advisers Inc. Co. raised its stake in shares of Boston Scientific Corporation by 21.3% in the third quarter. Icon Advisers Inc. Co. now owns 296,700 shares of the medical equipment provider’s stock worth $8,655,000 after acquiring an additional 52,100 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of Boston Scientific Corporation by 10.4% in the third quarter. Pacer Advisors Inc. now owns 27,714 shares of the medical equipment provider’s stock worth $808,000 after acquiring an additional 2,612 shares during the last quarter. Finally, Macquarie Group Ltd. raised its stake in shares of Boston Scientific Corporation by 7.9% in the third quarter. Macquarie Group Ltd. now owns 751,464 shares of the medical equipment provider’s stock worth $21,920,000 after acquiring an additional 54,999 shares during the last quarter. 90.68% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Boston Scientific Corporation (BSX) Shares Sold by TimesSquare Capital Management LLC” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/boston-scientific-corporation-bsx-shares-sold-by-timessquare-capital-management-llc/1723455.html.

Shares of Boston Scientific Corporation (NYSE BSX) opened at $28.47 on Friday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The firm has a market cap of $39,094.89, a P/E ratio of 23.34, a P/E/G ratio of 2.20 and a beta of 1.00. Boston Scientific Corporation has a 12 month low of $19.67 and a 12 month high of $29.93.

Boston Scientific Corporation (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.31. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. Boston Scientific Corporation’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.27 earnings per share. analysts predict that Boston Scientific Corporation will post 1.25 EPS for the current year.

In related news, EVP Timothy A. Pratt sold 10,104 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $27.46, for a total transaction of $277,455.84. Following the completion of the transaction, the executive vice president now owns 185,742 shares in the company, valued at $5,100,475.32. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Timothy A. Pratt sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $28.22, for a total transaction of $282,200.00. Following the transaction, the executive vice president now owns 164,681 shares of the company’s stock, valued at approximately $4,647,297.82. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 508,864 shares of company stock valued at $14,581,669. Corporate insiders own 0.74% of the company’s stock.

BSX has been the subject of a number of research analyst reports. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $31.00 target price on shares of Boston Scientific Corporation in a research note on Friday, September 1st. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $34.00 target price on shares of Boston Scientific Corporation in a research note on Monday, October 2nd. Stifel Nicolaus reissued a “buy” rating and set a $32.00 price target on shares of Boston Scientific Corporation in a research note on Monday, September 25th. UBS AG reissued a “buy” rating and set a $31.00 price target (up from $30.00) on shares of Boston Scientific Corporation in a research note on Tuesday, August 1st. Finally, Cowen Inc reissued a “buy” rating and set a $32.00 price target (up from $31.00) on shares of Boston Scientific Corporation in a research note on Friday, July 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Boston Scientific Corporation presently has an average rating of “Buy” and an average price target of $30.77.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.